Association of Antidepressant Use With Survival and Clinical Outcomes in Lung Cancer Patients Receiving PD-1/PD-L1 Immunotherapy
Lung cancer is a leading cause of cancer mortality. Immune checkpoint inhibitors targeting programmed cell death protein 1 (PD-1) or programmed death-ligand 1 (PD-L1) improve outcomes, but associations between antidepressant exposure and immunotherapy effectiveness remain uncertain.
Authors
- Mohammad Agha
- Syed Fahad Gillani
- Miriam Michael
- Muhammad Sajawal
- Rawan Elkomi Elkomi
- Banuja M.
- Emmanuel Maame
- Nicholas Azinge
Institutions
- Howard University (US)
- Howard College (US)
- Howard University Hospital (US)
Publication Details
- Journal
- Georgetown Medical Review
- Published
- 2026-09-09
- DOI
- https://doi.org/10.52504/001c.169245
- Primary Topic
- Cancer, Stress, Anesthesia, and Immune Response
- Type
- article
- Field-Weighted Citation Impact
- 0.00